Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
NCT01252355 · Sanofi · PHASE3 · terminated · last registry update 2014-06-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision to prematurely stop the study, not linked to any safety concern.” | – | Registry record, Sanofi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DHODH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-04-24Phase 3 first posted: Actelion, ponesimod + teriflunomide (NCT02425644)
- 2014-12-19Results posted on the registry: Sanofi, Teriflunomide + Placebo (NCT00622700)
- 2014-07-25Phase 3 first posted: Genzyme, a Sanofi Company, Teriflunomide + Placebo (NCT02201108)
- 2013-06-26Results posted on the registry: Sanofi, Placebo + Teriflunomide (NCT00751881)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision